Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Abiraterone acetate: a hat trick of clinical benefits.

Schweizer MT, Antonarakis ES.

Lancet Oncol. 2012 Dec;13(12):1173-4. doi: 10.1016/S1470-2045(12)70460-6. Epub 2012 Nov 9. No abstract available.

2.

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.

Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS.

Lancet Oncol. 2012 Dec;13(12):1210-7. doi: 10.1016/S1470-2045(12)70473-4. Epub 2012 Nov 9.

PMID:
23142059
3.

Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.

Bedoya DJ, Mitsiades N.

Expert Rev Anticancer Ther. 2012 Jan;12(1):1-3. doi: 10.1586/era.11.196. No abstract available.

PMID:
22149426
4.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Rehman Y, Rosenberg JE.

Drug Des Devel Ther. 2012;6:13-8. doi: 10.2147/DDDT.S15850. Epub 2012 Jan 16. Review.

5.

Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial.

Attard G, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, Dearnaley DP, Parker CC, Ritchie AW, Russell JM, Thalmann G, Cassoly E, Millman R, Matheson D, Schiavone F, Spears MR, Parmar MK, James ND.

Eur Urol. 2014 Nov;66(5):799-802. doi: 10.1016/j.eururo.2014.05.038. Epub 2014 Jun 27.

6.

Prostate cancer: The androgen receptor remains front and centre.

Saylor PJ.

Nat Rev Clin Oncol. 2013 Mar;10(3):126-8. doi: 10.1038/nrclinonc.2013.14. Epub 2013 Feb 5. Review. No abstract available.

PMID:
23381000
7.

[Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].

Turitto G, Di Bisceglie M, Moraca L, Sasso N, Sepede C, Suriano A, Romito S.

Recenti Prog Med. 2012 Feb;103(2):74-8. doi: 10.1701/1045.11391. Review. Italian.

PMID:
22430753
8.

Abiraterone and increased survival in metastatic prostate cancer.

Berruti A, Pia A, Terzolo M.

N Engl J Med. 2011 Aug 25;365(8):766; author reply 767-8. doi: 10.1056/NEJMc1107198#SA1. No abstract available.

PMID:
21864182
9.

Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer.

Tolcher AW, Chi KN, Shore ND, Pili R, Molina A, Acharya M, Kheoh T, Jiao JJ, Gonzalez M, Trinh A, Pankras C, Tran N.

Cancer Chemother Pharmacol. 2012 Aug;70(2):305-13. doi: 10.1007/s00280-012-1916-9. Epub 2012 Jul 3.

10.

Latent hypothyreosis as a clinical biomarker for therapy response under abiraterone acetate therapy.

Heidegger I, Nagele U, Pircher A, Pichler R, Horninger W, Bektic J.

Anticancer Res. 2014 Jan;34(1):307-11.

PMID:
24403479
11.

Re: J. Alfred Witjes. A case of abiraterone acetate withdrawal. Eur urol 2013;64:517-8.

Cronauer MV, Schrader MG, Schrader AJ.

Eur Urol. 2014 Jan;65(1):e10-1. doi: 10.1016/j.eururo.2013.08.035. Epub 2013 Aug 26. No abstract available.

PMID:
23993161
12.

Re: J. Alfred Witjes. A case of abiraterone acetate withdrawal. Eur Urol 2013;64:517-8.

Canipari C, Caroti C, Boccardo F.

Eur Urol. 2014 Apr;65(4):e54-5. doi: 10.1016/j.eururo.2013.11.038. Epub 2013 Dec 11. No abstract available.

PMID:
24341956
13.

[Abiraterone acetate (AA): current guidelines of prescription of abiraterone].

Boissier E, Loriot Y, Vignot S, Massard C.

Bull Cancer. 2014 Apr;101(4):388-93. doi: 10.1684/bdc.2014.1932. Review. French.

PMID:
24793632
14.

Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.

[No authors listed]

Med Lett Drugs Ther. 2011 Aug 25;53(1370):63-4. Review. No abstract available.

PMID:
21836546
15.

A case of abiraterone acetate withdrawal.

Witjes JA.

Eur Urol. 2013 Sep;64(3):517-8. doi: 10.1016/j.eururo.2013.06.013. Epub 2013 Jun 19. No abstract available.

PMID:
23806520
16.

Combination therapy: Abiraterone prolongs survival in metastatic prostate cancer.

Sartor O.

Nat Rev Clin Oncol. 2011 Aug 2;8(9):515-6. doi: 10.1038/nrclinonc.2011.111.

PMID:
21808270
17.

[CYP17A1 inhibitors in prostate cancer: mechanisms of action independent of the androgenic pathway].

Audenet F, Murez T, Ripert T, Villers A, Neuzillet Y.

Prog Urol. 2013 Oct;23 Suppl 1:S9-15. doi: 10.1016/S1166-7087(13)70041-1. Review. French.

PMID:
24314739
18.

Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer.

Chi KN, Tolcher A, Lee P, Rosen PJ, Kollmannsberger CK, Papadopoulos KP, Patnaik A, Molina A, Jiao J, Pankras C, Kaiser B, Bernard A, Tran N, Acharya M.

Cancer Chemother Pharmacol. 2013 Jan;71(1):237-44. doi: 10.1007/s00280-012-2001-0. Epub 2012 Oct 12.

PMID:
23064959
19.

Abiraterone and increased survival in metastatic prostate cancer.

Sonpavde G.

N Engl J Med. 2011 Aug 25;365(8):766-7; author reply 767-8. doi: 10.1056/NEJMc1107198#SA2. No abstract available.

PMID:
21864181
20.

Agents that target androgen synthesis in castration-resistant prostate cancer.

Ferraldeschi R, de Bono J.

Cancer J. 2013 Jan-Feb;19(1):34-42. doi: 10.1097/PPO.0b013e31827e0b6f. Review.

PMID:
23337755
Items per page

Supplemental Content

Write to the Help Desk